{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:49:25Z","timestamp":1790185765547,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02685-6","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:01:38Z","timestamp":1780527698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Xiuping","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouguang","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chujuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-9793","authenticated-orcid":false,"given":"Guangjun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-685X","authenticated-orcid":false,"given":"Jiandong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2685_CR1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2016.57","volume":"13","author":"Y Shaked","year":"2016","unstructured":"Shaked, Y. Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects. Nat. Rev. Clin. Oncol. 13, 611\u2013626 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2685_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.trecan.2023.02.001","volume":"9","author":"K H\u00e4nggi","year":"2023","unstructured":"H\u00e4nggi, K. & Ruffell, B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer 9, 381\u2013396 (2023).","journal-title":"Trends Cancer"},{"key":"2685_CR3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico, L. et al. A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J. Immunother. Cancer 7, 16 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"2685_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2685_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2219591","volume":"12","author":"J Sprooten","year":"2023","unstructured":"Sprooten, J. et al. Trial watch: chemotherapy-induced immunogenic cell death in oncology. Oncoimmunology 12, 2219591 (2023).","journal-title":"Oncoimmunology"},{"key":"2685_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","volume":"23","author":"G Kroemer","year":"2022","unstructured":"Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Immunogenic cell stress and death. Nat. Immunol. 23, 487\u2013500 (2022).","journal-title":"Nat. Immunol."},{"key":"2685_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nrc3380","volume":"12","author":"DV Krysko","year":"2012","unstructured":"Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860\u2013875 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"2685_CR8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/imr.13301","volume":"321","author":"S Janssens","year":"2024","unstructured":"Janssens, S., Rennen, S. & Agostinis, P. Decoding immunogenic cell death from a dendritic cell perspective. Immunol. Rev. 321, 350\u2013370 (2024).","journal-title":"Immunol. Rev."},{"key":"2685_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29606-9","volume":"13","author":"CR Bell","year":"2022","unstructured":"Bell, C. R. et al. Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations. Nat. Commun. 13, 2063 (2022).","journal-title":"Nat. Commun."},{"key":"2685_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nature14034","volume":"517","author":"AV Kurtova","year":"2015","unstructured":"Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209\u2013213 (2015).","journal-title":"Nature"},{"key":"2685_CR11","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341\u20131358.e1311 (2023).","journal-title":"Immunity"},{"key":"2685_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher, S. B. et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature 629, 417\u2013425 (2024).","journal-title":"Nature"},{"key":"2685_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","volume":"629","author":"M Morotti","year":"2024","unstructured":"Morotti, M. et al. PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629, 426\u2013434 (2024).","journal-title":"Nature"},{"key":"2685_CR14","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1073\/pnas.1602023113","volume":"113","author":"S Hangai","year":"2016","unstructured":"Hangai, S. et al. PGE2 induced in and released by dying cells functions as an inhibitory DAMP. Proc. Natl. Acad. Sci. USA 113, 3844\u20133849 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2685_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.clinthera.2014.06.015","volume":"36","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clin. Ther. 36, 1253\u20131263 (2014).","journal-title":"Clin. Ther."},{"key":"2685_CR16","doi-asserted-by":"publisher","first-page":"e13973","DOI":"10.1111\/eci.13973","volume":"53","author":"L Li","year":"2023","unstructured":"Li, L., Zhang, Y. & Qin, L. Effect of celecoxib plus standard chemotherapy on cancer prognosis: a systematic review and meta-analysis. Eur. J. Clin. Investig. 53, e13973 (2023).","journal-title":"Eur. J. Clin. Investig."},{"key":"2685_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","volume":"325","author":"JA Meyerhardt","year":"2021","unstructured":"Meyerhardt, J. A. et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer. JAMA 325, 1277\u20131286 (2021).","journal-title":"JAMA"},{"key":"2685_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adu6989","volume":"17","author":"X Jiao","year":"2025","unstructured":"Jiao, X. et al. Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer. Sci. Transl. Med. 17, eadu6989 (2025).","journal-title":"Sci. Transl. Med."},{"key":"2685_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ram\u00edrez-Valle","year":"2024","unstructured":"Ram\u00edrez-Valle, F., Maranville, J. C., Roy, S. & Plenge, R. M. Sequential immunotherapy: towards cures for autoimmunity. Nat. Rev. Drug Discov. 23, 501\u2013524 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2685_CR20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(16)30126-7","volume":"17","author":"JS Weber","year":"2016","unstructured":"Weber, J. S. et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 17, 943\u2013955 (2016).","journal-title":"Lancet Oncol."},{"key":"2685_CR21","doi-asserted-by":"publisher","first-page":"e137066","DOI":"10.1172\/jci.insight.137066","volume":"5","author":"DM Woods","year":"2020","unstructured":"Woods, D. M. et al. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight 5, e137066 (2020).","journal-title":"JCI Insight"},{"key":"2685_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.immuni.2024.03.002","volume":"57","author":"M Ma","year":"2024","unstructured":"Ma, M., Jiang, W. & Zhou, R. DAMPs and DAMP-sensing receptors in inflammation and diseases. Immunity 57, 752\u2013771 (2024).","journal-title":"Immunity"},{"key":"2685_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53706-3","volume":"15","author":"S Punyawatthananukool","year":"2024","unstructured":"Punyawatthananukool, S. et al. Prostaglandin E2-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. Nat. Commun. 15, 9464 (2024).","journal-title":"Nat. Commun."},{"key":"2685_CR24","doi-asserted-by":"publisher","first-page":"110914","DOI":"10.1016\/j.celrep.2022.110914","volume":"39","author":"D Thumkeo","year":"2022","unstructured":"Thumkeo, D. et al. PGE2-EP2\/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment. Cell Rep. 39, 110914 (2022).","journal-title":"Cell Rep."},{"key":"2685_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08180-0","volume":"16","author":"Z Xie","year":"2025","unstructured":"Xie, Z. et al. The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy. Cell Death Dis. 16, 900 (2025).","journal-title":"Cell Death Dis."},{"key":"2685_CR26","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. BMJ. 381, e071674 (2023).","journal-title":"BMJ."},{"key":"2685_CR27","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/jcm12041524","volume":"12","author":"J Lee","year":"2023","unstructured":"Lee, J. Current treatment landscape for early triple-negative breast cancer (TNBC). J. Clin. Med. 12, 1524 (2023).","journal-title":"J. Clin. Med."},{"key":"2685_CR28","doi-asserted-by":"publisher","first-page":"791696","DOI":"10.3389\/fonc.2021.791696","volume":"11","author":"OL Walker","year":"2021","unstructured":"Walker, O. L., Dahn, M. L., Power Coombs, M. R. & Marcato, P. The prostaglandin E2 pathway and breast cancer stem cells: evidence of increased signaling and potential targeting. Front. Oncol. 11, 791696 (2021).","journal-title":"Front. Oncol."},{"key":"2685_CR29","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3390\/ijms19041019","volume":"19","author":"M Majumder","year":"2018","unstructured":"Majumder, M., Nandi, P., Omar, A., Ugwuagbo, K. C. & Lala, P. K. EP4 as a therapeutic target for aggressive human breast cancer. Int. J. Mol. Sci. 19, 1019 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2685_CR30","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1001\/jamaoncol.2021.2193","volume":"7","author":"RC Coombes","year":"2021","unstructured":"Coombes, R. C. et al. Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer. JAMA Oncol. 7, 1291\u20131301 (2021).","journal-title":"JAMA Oncol."},{"key":"2685_CR31","doi-asserted-by":"publisher","first-page":"101070","DOI":"10.1016\/j.pmatsci.2023.101070","volume":"134","author":"X Kong","year":"2023","unstructured":"Kong, X. et al. Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer. Prog. Mater. Sci. 134, 101070 (2023).","journal-title":"Prog. Mater. Sci."},{"key":"2685_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.152","volume":"8","author":"L Chen","year":"2017","unstructured":"Chen, L. et al. cPLA2\u03b1 mediates TGF-\u03b2-induced epithelial-mesenchymal transition in breast cancer through PI3k\/Akt signaling. Cell Death Dis. 8, e2728 (2017).","journal-title":"Cell Death Dis."},{"key":"2685_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.canlet.2020.10.021","volume":"497","author":"Z Peng","year":"2021","unstructured":"Peng, Z. et al. Phospholipase A2 superfamily in cancer. Cancer Lett. 497, 165\u2013177 (2021).","journal-title":"Cancer Lett."},{"key":"2685_CR34","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1021\/jm100190c","volume":"53","author":"PJ Pedersen","year":"2010","unstructured":"Pedersen, P. J. et al. Liposomal formulation of retinoids designed for enzyme-triggered release. J. Med. Chem. 53, 3782\u20133792 (2010).","journal-title":"J. Med. Chem."},{"key":"2685_CR35","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0168-3659(02)00206-7","volume":"83","author":"AJ Schraa","year":"2002","unstructured":"Schraa, A. J. et al. Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. J. Control. Release 83, 241\u2013251 (2002).","journal-title":"J. Control. Release"},{"key":"2685_CR36","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.1633689100","volume":"100","author":"M Rolli","year":"2003","unstructured":"Rolli, M., Fransvea, E., Pilch, J., Saven, A. & Felding-Habermann, B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc. Natl. Acad. Sci. USA 100, 9482\u20139487 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2685_CR37","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1021\/ac400009s","volume":"85","author":"Z Luo","year":"2013","unstructured":"Luo, Z. et al. Air flow-assisted ionization imaging mass spectrometry method for easy whole-body molecular imaging under ambient conditions. Anal. Chem. 85, 2977\u20132982 (2013).","journal-title":"Anal. Chem."},{"key":"2685_CR38","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel, N., Najafi, M., Salehi, E., Farhood, B. & Mortezaee, K. Cyclooxygenase-2 in cancer: a review. J. Cell. Physiol. 234, 5683\u20135699 (2019).","journal-title":"J. Cell. Physiol."},{"key":"2685_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.bcp.2018.05.013","volume":"154","author":"R Pritchard","year":"2018","unstructured":"Pritchard, R. et al. Celecoxib inhibits mitochondrial O(2) consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway. Biochem. Pharmacol. 154, 318\u2013334 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"2685_CR40","doi-asserted-by":"publisher","first-page":"21197","DOI":"10.1074\/jbc.M113.484576","volume":"288","author":"S Arora","year":"2013","unstructured":"Arora, S. et al. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor \u03baB- and hypoxia-inducible factor 1\u03b1-mediated up-regulation of CXCR4. J. Biol. Chem. 288, 21197\u201321207 (2013).","journal-title":"J. Biol. Chem."},{"key":"2685_CR41","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1158\/2159-8290.CD-21-0764","volume":"11","author":"A Grover","year":"2021","unstructured":"Grover, A., Sanseviero, E., Timosenko, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells: a propitious road to clinic. Cancer Discov. 11, 2693\u20132706 (2021).","journal-title":"Cancer Discov."},{"key":"2685_CR42","doi-asserted-by":"publisher","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","volume":"153","author":"KGK Deepak","year":"2020","unstructured":"Deepak, K. G. K. et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol. Res. 153, 104683 (2020).","journal-title":"Pharmacol. Res."},{"key":"2685_CR43","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","volume":"186","author":"S Gerstberger","year":"2023","unstructured":"Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564\u20131579 (2023).","journal-title":"Cell"},{"key":"2685_CR44","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41569-020-0366-z","volume":"17","author":"AM Schjerning","year":"2020","unstructured":"Schjerning, A. M., McGettigan, P. & Gislason, G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. 17, 574\u2013584 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"2685_CR45","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala, N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382, 769\u2013779 (2013).","journal-title":"Lancet"},{"key":"2685_CR46","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1016\/j.molcel.2025.09.007","volume":"85","author":"R Chen","year":"2025","unstructured":"Chen, R., Zou, J., Liu, J., Kang, R. & Tang, D. DAMPs in the immunogenicity of cell death. Mol. Cell 85, 3874\u20133889 (2025).","journal-title":"Mol. Cell"},{"key":"2685_CR47","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41568-025-00903-x","volume":"26","author":"LB Darragh","year":"2026","unstructured":"Darragh, L. B. & Karam, S. D. Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy. Nat. Rev. Cancer 26, 270\u2013284 (2026).","journal-title":"Nat. Rev. Cancer"},{"key":"2685_CR48","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang, Y. et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 109, 17561\u201317566 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2685_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y","volume":"15","author":"I Telarovic","year":"2024","unstructured":"Telarovic, I. et al. Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease. Nat. Commun. 15, 5500 (2024).","journal-title":"Nat. Commun."},{"key":"2685_CR50","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","volume":"18","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E. & Adinolfi, E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat. Rev. Cancer 18, 601\u2013618 (2018).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02685-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02685-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:01:39Z","timestamp":1780527699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02685-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2685"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02685-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests or personal relationships that could have influenced the work presented in this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"215"}}